National Bank of Canada FI Has $11.35 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

National Bank of Canada FI lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 26.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 93,480 shares of the medical equipment provider’s stock after selling 32,889 shares during the period. National Bank of Canada FI’s holdings in Zimmer Biomet were worth $11,347,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. PFG Advisors lifted its holdings in Zimmer Biomet by 4.6% in the fourth quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock valued at $231,000 after buying an additional 84 shares during the period. Quent Capital LLC lifted its stake in shares of Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock valued at $63,000 after purchasing an additional 92 shares during the period. Financial Advocates Investment Management boosted its position in shares of Zimmer Biomet by 3.8% during the 3rd quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider’s stock valued at $295,000 after purchasing an additional 97 shares in the last quarter. Stokes Family Office LLC grew its stake in Zimmer Biomet by 4.1% during the third quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider’s stock worth $280,000 after purchasing an additional 99 shares during the period. Finally, Parkside Financial Bank & Trust increased its holdings in Zimmer Biomet by 15.6% in the third quarter. Parkside Financial Bank & Trust now owns 756 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 102 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of research analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. Barclays raised their price objective on Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research note on Monday, February 12th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $130.00 target price on shares of Zimmer Biomet in a research report on Friday, February 23rd. Truist Financial reduced their price target on shares of Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating for the company in a research report on Friday, May 3rd. Finally, Oppenheimer raised their price objective on shares of Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $135.40.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.70% of the stock is owned by corporate insiders.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $120.85 on Thursday. The stock has a 50 day moving average of $125.07 and a 200 day moving average of $120.44. The company has a current ratio of 1.66, a quick ratio of 0.80 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $147.50. The company has a market capitalization of $24.86 billion, a price-to-earnings ratio of 26.16, a PEG ratio of 2.18 and a beta of 1.03.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same period in the previous year, the firm earned $1.89 EPS. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.09 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were paid a $0.24 dividend. The ex-dividend date was Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.79%. Zimmer Biomet’s payout ratio is 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.